[1]Cowan AJ, Green DJ, Kwok M, et al. Diagnosis and management of multiple myeloma: a review[J]. JAMA, 2022, 327: 464-477. [2]张永梅,张志敏,周洁,等. LncRNA CBR3-AS1在多发性骨髓瘤中的表达及临床意义[J].基础医学与临床,2023,43:948-952. [3]Fang W, Mu J, Yang Y, et al. CircRERE confers the resistance of multiple myeloma to bortezomib depending on the regulation of CD47 by exerting the sponge effect on miR-152-3p[J]. J Bone Oncol, 2021, 30: 100381. doi: 10.1016/j.jbo.2021.100381 [4]Zhou F, Wang D, Wei W, et al. Comprehensive profiling of circular RNA expressions reveals potential diagnostic and prognostic biomarkers in multiple myeloma[J]. BMC Cancer, 2020, 20: 40. doi: 10.1186/s12885-020-6515-2. [5]Liu Q, Ran R, Song M, et al. LncRNA HCP5 acts as a miR-128-3p sponge to promote the progression of multiple myeloma through activating Wnt/β-catenin/cyclin D1 signaling via PLAGL2[J]. Cell Biol Toxicol, 2022, 38: 979-993. [6]Ghelli Luserna di Rorà A, Cerchione C, Martinelli G, et al. A WEE1 family business: regulation of mitosis, cancer progression, and therapeutic target[J]. J Hematol Oncol, 2020, 13: 126-142. [7]Ling Z, Zhang J, Liu Q. Oncogenic Forkhead box D3 antisense RNA 1 promotes cell survival and confers temozolomide resistance in glioblastoma cells through the miR-128-3p/WEE1 G2 checkpoint kinase axis[J]. Bioengineered, 2022, 13: 6012-6023. [8]Jakobsen T, Dahl M, Dimopoulos K, et al. Genome-wide circular RNA expression patterns reflect resistance to immunomodulatory drugs in multiple myeloma cells[J]. Cancers (Basel), 2021, 13: 365-383. [9]Chen D, Yang X, Liu M, et al. Roles of miRNA dysregulation in the pathogenesis of multiple myeloma[J]. Cancer Gene Ther, 2021, 28: 1256-1268. [10]杨芒庄,杨旭东,王晓龙. Circ-MALAT1靶向miR-101抑制膀胱癌细胞系SW780侵袭和迁移[J]. 基础医学与临床,2022,42:472-478. [11]Feng Y, Zhang L, Wu J, et al. CircRNA circ_0000190 inhibits the progression of multiple myeloma through modulating miR-767-5p/MAPK4 pathway[J]. J Exp Clin Cancer Res, 2019, 38: 54-70. [12]Wang Y, Lin Q, Song C, et al. Depletion of circ_0007841 inhibits multiple myeloma development and BTZ resistance via miR-129-5p/JAG1 axis[J]. Cell Cycle, 2020, 19:3289-3302. [13]Gorecki L, Andrs M, Korabecny J. Clinical candidates targeting the ATR-CHK1-WEE1 axis in cancer[J]. Cancers (Basel), 2021, 13: 795-816. [14]华科雷,任莹坤,霍明科,等. miR-128-3p在胃癌组织中的表达及其对胃癌细胞迁移和侵袭能力的影响[J]. 中华普通外科杂志,2022,37:279-283. |